Top

Published in:

01-03-2006 | Symposium in Writing

Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression

Authors: Akira Ito, Hiroyuki Honda, Takeshi Kobayashi

Published in: Cancer Immunology, Immunotherapy | Issue 3/2006

Abstract

Heat shock proteins (HSPs) are highly conserved proteins whose syntheses are induced by a variety of stresses, including heat stress. Since the expression of HSPs, including HSP70, protects cells from heat-induced apoptosis, HSP expression has been considered to be a complicating factor in hyperthermia. On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90 and glucose-regulated protein 96 (gp96), in immune reactions. If HSP expression induced by hyperthermia is involved in tumor immunity, novel cancer immunotherapy based on this novel concept can be developed. In such a strategy, a tumor-specific hyperthermia system, which can heat the local tumor region to the intended temperature without damaging normal tissue, would be highly advantageous. To achieve tumor-specific hyperthermia, we have developed an intracellular hyperthermia system using magnetite nanoparticles. This novel hyperthermia system can induce necrotic cell death via HSP expression, which induces antitumor immunity. In the present article, cancer immunology and immunotherapy based on hyperthermia, and HSP expression are reviewed and discussed.

Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK (2000) HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperon and cytokine. Nat Med 6:435–442PubMedCrossRef

Basu S, Binder R, Suto R, Anderson KM, Srivastava PK (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NFkB pathway. Int Immunol 12:1539–1546PubMedCrossRef

Becker T, Hartl FU, Wieland F (2002) CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 158:1277–1285PubMedCrossRef

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180PubMedCrossRef

Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M, Mazzaferro V, Coppa J, Srivastava PK, Parmiani G (2004) Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 53:227–233PubMedCrossRef

Chandawarkar RY, Wagh MS, Kovalchin JT, Srivastava P (2004) Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol 16:615–624PubMedCrossRef

Dewey WC, Hopwood LE, Sapareto LA, Gerweck LE (1977) Cellular responses to combinations of hyperthermia and radiation. Radiology 123:463–474PubMed

Dressel R, Lubbers M, Walter L, Herr W, Gunther E (1999) Enhanced susceptibility to cytotoxic T lymphocytes without increase of MHC class I antigen expression after conditional overexpression of heat shock protein 70 in target cells. Eur J Immunol 29:3925–3935PubMedCrossRef

Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985–7994PubMedCrossRef

10.

Gordon RT, Hines JR, Gordon D (1979) Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med Hypothesis 5:83–102CrossRef

11.

Hauser H, Shen L, Gu QL, Krueger S, Chen SY (2004) Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11:924–932PubMedCrossRef

12.

Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T (2003) Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng 96:364–369PubMed

13.

Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (2001) Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 50:515–522PubMedCrossRef

14.

Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T (2003) Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 52:80–88PubMed

15.

Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 212:167–175PubMedCrossRef

16.

Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T (2003) Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 94:308–313PubMedCrossRef

17.

Ito A, Shinkai M, Honda H, Kobayashi T (2001) Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 8:649–654PubMedCrossRef

18.

Ito A, Matsuoka M, Honda H, Kobayashi T (2004) Anititumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother 53:26–32PubMedCrossRef

19.

Ito A, Matsuoka M, Honda H, Kobayashi T (2003) Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther 10:918–925PubMedCrossRef

20.

Jordan A, Wust P, Fähling H, John W, Hinz A, Felix R (1993) Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 9:51–68PubMedCrossRef

21.

Jordan A, Wust P, Scholz R, Tesch B, Fähling H, Mitrovics T, Vogl T, Cervós-Navarro J, Felix R (1996) Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 12:705–722PubMedCrossRef

22.

Kato N, Kobayashi T, Honda H (2003) Screening of stress enhancer based on analysis of gene expression profiles: enhancement of hyperthermia-induced tumor necrosis by an MMP-3 inhibitor. Cancer Sci 94:644–649PubMedCrossRef

23.

Labarriere N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E, Lang F, Gregoire M, Jotereau F (2002) Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer 101:280–286PubMedCrossRef

24.

Le B, Shinkai M, Kitade T, Honda H, Yoshida J, Wakabayashi T, Kobayashi T (2001) Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jpn 34:66–72CrossRef

25.

Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55:1151–1191PubMedCrossRef

26.

Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C (2004) Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 64:1502–1508PubMedCrossRef

27.

Matsuoka F, Shinkai M, Honda H, Kubo T, Sugita T, Kobayashi T (2004) Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagn Res Technol 2:3PubMedCrossRef

28.

Matsuno H, Tohnai I, Mitsudo K, Hayashi Y, Ito M, Shinkai M, Kobayashi T, Yoshida J, Ueda M (2001) Interstitial hyperthermia using magnetite cationic liposomes inhibit to tumor growth of VX-7 transplanted tumor in rabbit tongue. Jpn J Hyperthermic Oncol 17:141–149

29.

Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchiano A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9:3235–3245PubMed

30.

Ménoret A, Chandawarkar R (1998) Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Sem Immunol 25:654–660

31.

Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, Gastpar R, Issels RD (2002) Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia 18:563–575PubMedCrossRef

32.

Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 18:267–284PubMedCrossRef

33.

Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B (2000) The chaperon function of hsp 70 is required for protection against stress-induced apoptosis. Mol Cell Biol 20:7146–7159PubMedCrossRef

34.

Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1996) Intracellular hyperthermia for cancer using magnetite cationic liposome: in vitro study. Jpn J Cancer Res 87:1179–1183PubMed

35.

Shinkai M, Le B, Honda H, Yoshikawa K, Shimizu K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T (2001) Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J Cancer Res 92:1138–1145PubMed

36.

Srivastava PK, Ménoret A, Basu S, Binder R, Quade K (1998) Heat shock proteins come of age: primitive functions acquired new roles in an adaptive world. Immunity 8:657–665PubMedCrossRef

37.

Srivastava PK, Maki RG (1991) Stress-induced proteins in immune response to cancer. Curr Top Microbiol Immunol 167:109–123PubMed

38.

Srivastava PK, Heike M (1993) Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Semin Immunol 3:57–64

39.

Srivastava PK, Udono H, Blachere NE, Li Z (1994) Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93–98PubMedCrossRef

40.

Srivastava PK (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185–194PubMedCrossRef

41.

Srivastava PK (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425PubMedCrossRef

42.

Subjeck JR, Sciandra JJ, Chao CF, Johnson RJ (1982) Heat shock proteins and biological response to hyperthermia. Br J Cancer 45:127–131

43.

Subjeck JR, Sciandra JJ, Johnson RJ (1982) Heat shock proteins and thermotolerance; a comparison of induction kinetics. Br J Radiol 55:579–584PubMedCrossRef

44.

Suzuki M, Shinkai M, Honda H, Kobayashi T (2003) Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 13:129–135PubMedCrossRef

45.

Tanaka A, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H (2005) Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer 116:624–633PubMedCrossRef

46.

Tanaka A, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H (2005) Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. J Bio Bioeng 100:112–115PubMedCrossRef

47.

Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG (1999) Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163:1398–1408PubMed

48.

Udono H, Srivastava PK (1994) Comparison of tumor-specific immunogenicities of stress-induced protein gp96, hsp90, and hsp70. J Immunol 152:5398–5403PubMed

49.

Van der Zee J (2002) Heating the patient: a promising approach? Annu Oncol 13:1173–1184CrossRef

50.

Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M (1998) Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 10:609–617PubMedCrossRef

51.

Wells AD, Malkovsky M (2000) Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 21:129–132PubMedCrossRef

52.

Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1998) Intracellular hyperthermia for cancer using magnetite cationic liposome: an in vivo study. Jpn J Cancer Res 89:463–469PubMed

53.

Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T (1998) Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 89:775–782PubMed

54.

Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF (2004) Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53:825–834PubMedCrossRef

55.

Yonezawa M, Ohtsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A, Kato T (1996) Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer 66:347–351PubMedCrossRef

Title: Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression
Authors: Akira Ito
Hiroyuki Honda
Takeshi Kobayashi
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-005-0049-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model

Effects of thermal stress on tumor antigenicity and recognition by immune effector cells

Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer

Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function

Thermal stress-related modulation of tumor cell physiology and immune responses

Dynamic control of lymphocyte trafficking by fever-range thermal stress

Keynote webinar | Spotlight on antibody–drug conjugates in cancer